| |
| |
|
| Insider
Information: |
Karabelas Argeris N |
| Relationship: |
|
| City: |
Princeton |
| State: |
NJ |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
130,211 |
|
|
Indirect Shares
|
3,405,909 |
|
|
| Direct
Value |
$1,182,728 |
|
|
|
Indirect Value
|
$50,051,515 |
|
|
| Total
Shares |
3,536,120 |
|
|
| Total
Value |
$51,234,243 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Anadys Pharmaceuticals Inc |
ANDS |
Director |
|
0 |
2004-03-18 |
1,128,770 |
Premium* |
|
|
Vanda Pharmaceuticals Inc. |
VNDA |
Director |
|
0 |
2010-03-12 |
0 |
Premium* |
|
|
Biodelivery Sciences Internation... |
BDSI |
10% Owner |
2009-06-17 |
0 |
2009-07-16 |
0 |
Premium* |
|
|
Human Genome Sciences Inc |
HGSI |
Director |
2012-07-30 |
0 |
2006-11-10 |
0 |
Premium* |
|
|
Rocket Pharmaceuticals |
RCKT |
Director, 10% Owner |
|
0 |
2015-02-23 |
2,277,139 |
Premium* |
|
|
Bausch Health Companies Inc |
BHC |
Director |
2022-06-24 |
123,715 |
2016-06-17 |
0 |
Premium* |
|
|
Regenxbio Inc. |
RGNX |
|
2023-06-02 |
6,496 |
2022-06-03 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| RGNX |
Regenxbio Inc. |
|
– • – |
2023-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
3,486 |
6,496 |
0 |
- |
|
| BHC |
Bausch Health Companies I... |
Director |
• • – |
2022-06-24 |
4 |
A |
$0.00 |
$0 |
D/D |
34,387 |
123,715 |
0 |
- |
|
| RGNX |
Regenxbio Inc. |
|
– • – |
2022-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
3,010 |
3,010 |
0 |
- |
|
| BHC |
Bausch Health Companies I... |
Director |
• • – |
2021-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
7,645 |
89,328 |
0 |
- |
|
| BHC |
Bausch Health Companies I... |
Director |
• • – |
2020-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
11,037 |
81,683 |
0 |
- |
|
| BHC |
Bausch Health Companies I... |
Director |
• • – |
2019-05-03 |
4 |
A |
$23.51 |
$249,982 |
D/D |
10,633 |
70,646 |
0 |
- |
|
| BHC |
Bausch Health Companies I... |
Director |
• • – |
2018-05-03 |
4/A |
A |
$0.00 |
$0 |
D/D |
13,881 |
60,013 |
0 |
- |
|
| BHC |
Bausch Health Companies I... |
Director |
• • – |
2018-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
14,285 |
60,417 |
0 |
- |
|
| BHC |
Bausch Health Companies I... |
Director |
– • – |
2017-05-05 |
4 |
A |
$0.00 |
$0 |
D/D |
25,406 |
46,132 |
0 |
- |
|
| BHC |
Bausch Health Companies I... |
Director |
– • – |
2016-08-11 |
4 |
B |
$24.65 |
$98,600 |
D/D |
4,000 |
20,726 |
2.39 |
- |
|
| BHC |
Bausch Health Companies I... |
Director |
– • – |
2016-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
16,726 |
16,726 |
0 |
- |
|
| RCKT |
Rocket Pharmaceuticals |
Director |
– • • |
2015-02-23 |
4 |
B |
$6.00 |
$3,622,992 |
I/I |
603,832 |
2,277,139 |
2.25 |
- |
|
| RCKT |
Rocket Pharmaceuticals |
Director |
– • • |
2015-02-23 |
4 |
A |
$0.00 |
$0 |
I/I |
1,458,205 |
1,673,307 |
0 |
- |
|
| RCKT |
Rocket Pharmaceuticals |
Director |
– • • |
2015-02-17 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
215,102 |
|
- |
|
| HGSI |
Human Genome Sciences Inc |
Director |
• • – |
2012-07-30 |
4 |
D |
$14.25 |
$253,308 |
D/D |
(17,776) |
0 |
0 |
- |
|
| HGSI |
Human Genome Sciences Inc |
Director |
• • – |
2012-07-30 |
4 |
D |
$14.25 |
$59,366 |
D/D |
(4,166) |
17,776 |
0 |
- |
|
| HGSI |
Human Genome Sciences Inc |
Director |
• • – |
2012-07-10 |
4 |
A |
$13.64 |
$9,930 |
D/D |
728 |
21,942 |
0 |
- |
|
| HGSI |
Human Genome Sciences Inc |
Director |
– • – |
2012-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
21,214 |
0 |
- |
|
| HGSI |
Human Genome Sciences Inc |
Director |
– • – |
2012-04-10 |
4 |
A |
$7.53 |
$8,434 |
D/D |
1,120 |
18,714 |
0 |
- |
|
| HGSI |
Human Genome Sciences Inc |
Director |
– • – |
2012-01-10 |
4 |
A |
$8.03 |
$9,933 |
D/D |
1,237 |
17,594 |
0 |
- |
|
| HGSI |
Human Genome Sciences Inc |
Director |
– • – |
2011-10-10 |
4 |
A |
$11.13 |
$8,303 |
D/D |
746 |
16,357 |
0 |
- |
|
| HGSI |
Human Genome Sciences Inc |
Director |
– • – |
2011-07-10 |
4 |
A |
$24.52 |
$7,430 |
D/D |
303 |
15,611 |
0 |
- |
|
| HGSI |
Human Genome Sciences Inc |
Director |
– • – |
2011-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
15,308 |
0 |
- |
|
| HGSI |
Human Genome Sciences Inc |
Director |
– • – |
2011-04-10 |
4 |
A |
$28.74 |
$8,852 |
D/D |
308 |
12,808 |
0 |
- |
|
| VNDA |
Vanda Pharmaceuticals Inc... |
Director |
– • – |
2010-03-12 |
4 |
S |
$11.80 |
$2,360,000 |
I/I |
(200,000) |
0 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
